Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Cited by (1,012)

Items 101–200 of 1,012

1. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
   Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo et al. · 2022 · International Journal of Molecular Sciences
2. Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside
   Hao Zhou, Jun Tao Ren, Sam Toan, David Mui · 2020 · Ageing Research Reviews
3. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024
   Yael Peled, Anique Ducharme, Michelle Maya Kittleson, Neha Bansal, Josef Stehlik, Shahnawaz M. Amdani, Diyar Saeed, Richard Cheng, Brian A. Clarke, Fabienne Dobbels et al. · 2024 · The Journal of Heart and Lung Transplantation
4. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
   Spertus, John A., Birmingham, Mary C., Nassif, Michael, Damaraju, C. V., Abbate, Antonio, Butler, Javed, Lanfear, David E., Lingvay, Ildiko, Kosiborod, Mikhail N., Januzzi, James L. · 2022 · Nature Medicine
5. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
   Clifford J. Bailey, Caroline Day, Srikanth Bellary · 2022 · Current Diabetes Reports
6. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
   Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay et al. · 2021 · The Lancet Diabetes & Endocrinology
7. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
   Navaneethan, Sankar D., Zoungas, Sophia, Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Liew, Adrian, Michos, Erin D., Olowu, Wasiu A., Sadusky, Tami et al. · 2023 · Annals of Internal Medicine
8. Pharmacological treatment of hyperglycemia in type 2 diabetes
   Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees · 2021 · Journal of Clinical Investigation
9. Coronary heart disease risk: Low-density lipoprotein and beyond
   Gabriel E. Shaya, Thorsten Martin Leucker, Steven Richard Jones, Seth Shay Martin, Peter Paul Toth · 2021 · Trends in Cardiovascular Medicine
10. Protective Factors and the Pathogenesis of Complications in Diabetes
    Marc Gregory Yu, Daniel Gordin, Jialin Fu, Kyoungmin Park, Qian Li, George Liang King · 2023 · Endocrine Reviews
11. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
    Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G.C. Van Spall, Jozine M. ter Maaten, Kevin Damman · 2022 · Circulation
12. Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease
    Salva R. Yurista, Cher‐Rin Chong, Juan J. Badimón, Daniel P. Kelly, Rudolf A. de Boer, Berend Daan Westenbrink · 2021 · Journal of the American College of Cardiology
13. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo‐Kyung Kim, Seung‐Hwan Lee, Jae‐Seung Yun, Jong Ha Baek, Junghyun Noh, Byung‐Wan Lee, Tae Jung Oh et al. · 2021 · Diabetes & Metabolism Journal
14. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
    Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z.I. Cherney · 2022 · Kidney International Reports
15. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
    Paul Christian Schulze, Jürgen Bogoviku, Julian Georg Westphal, Pawel Aftanski, Franz Haertel, Sissy Grund, Stephan von Haehling, Ulrike Schumacher, Sven Möbius‐Winkler, Martin Busch · 2022 · Circulation
16. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
    Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, Antonella Pansini, Angela Lombardi, Salvatore Frullone, Gaetano Santulli · 2022 · Hypertension
17. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
    Abraham, William T, Lindenfeld, JoAnn, Ponikowski, Piotr, Agostoni, Piergiuseppe, Butler, Javed, Desai, Akshay S, Filippatos, Gerasimos, Gniot, Jacek, Fu, Michael, Gullestad, Lars et al. · 2021 · European Heart Journal
18. Cardiovascular disease in diabetes, beyond glucose
    Robert H. Eckel, Karin Bornfeldt, Ira J. Goldberg · 2021 · Cell Metabolism
19. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
    Kraus, Bettina J., Weir, Matthew R., Bakris, George L., Mattheus, Michaela, Cherney, David Z.I., Sattar, Naveed, Heerspink, Hiddo J.L., Ritter, Ivana, von Eynatten, Maximilian, Zinman, Bernard et al. · 2021 · Kidney International
20. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
21. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
    Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Wentong Long, Shubham Soni, Nikole J. Byrne, Amy Barr, Jyoti Singh, Jordan A. Wong, Taylor Palechuk et al. · 2021 · Circulation
22. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
    Siddharth M. Patel, Yu Mi Kang, KyungAh Im, Brendon Lange Neuen, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, Brian Lee Claggett, Robert A. Fletcher et al. · 2024 · Circulation
23. Effects of dapagliflozin in stage 4 chronic kidney disease
    Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David et al. · 2021 · Journal of the American Society of Nephrology
24. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
25. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
    Alicic, Radica Z., Cox, Emily J., Neumiller, Joshua J., Tuttle, Katherine R. · 2021 · Nature Reviews Nephrology
26. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, Janusz Gumprecht, Tomasz P. Stompór · 2021 · International Journal of Molecular Sciences
27. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
    Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou · 2022 · Cardiovascular Diabetology
28. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Circulation Journal
29. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
    Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Ferreira, João Pedro, Pocock, Stuart J, Giannetti, Nadia, Januzzi, James L, Piña, Ileana L, Lam, Carolyn S P et al. · 2021 · European Heart Journal
30. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
    Milton Packer · 2023 · Nature Reviews Cardiology
31. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
    Khawaja Muhammad Talha, Stefan D. Anker, Javed Butler · 2023 · International Journal of Heart Failure
32. Ketones and the Heart: Metabolic Principles and Therapeutic Implications
    Timothy R. Matsuura, Patrycja Puchalska, Peter A. Crawford, Daniel P. Kelly · 2023 · Circulation Research
33. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis
    Tsapas, Apostolos, Karagiannis, Thomas, Kakotrichi, Panagiota, Avgerinos, Ioannis, Mantsiou, Chrysanthi, Tousinas, Georgios, Manolopoulos, Apostolos, Liakos, Aris, Malandris, Konstantinos, Matthews, David R. et al. · 2021 · Diabetes, Obesity and Metabolism
34. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis
    Xiaoling Li, Nina Claudia Weber, Danny M. Cohn, Markus Werner Hollmann, J. Hans DeVries, Jeroen Hermanides, Benedikt Preckel · 2021 · Journal of Clinical Medicine
35. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
    Shruti Shree Joshi, Trisha Singh, David Ernest Newby, Jagdeep S. Singh · 2021 · Heart
36. Sex Differences in Heart Failure
    Anuradha Lala, Upasana Tayal, CARINE E. HAMO, Quentin R. Youmans, Sana M. Al‐Khatib, Biykem Bozkurt, Melinda Baughman Davis, James L. Januzzi, Robert John Mentz, Andrew J. Sauer et al. · 2021 · Journal of Cardiac Failure
37. Heart failure with preserved ejection fraction
    CARINE E. HAMO, Colette DeJong, Nick Hartshorne‐Evans, Lars H. Lund, Sanjiv Jayendra Shah, Scott David Solomon, Carolyn S.P. Lam · 2024 · Nature Reviews Disease Primers
38. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction
    Massar Omar, Jesper Jensen, Mulham Ali, Peter Hartmund Frederiksen, Caroline Kistorp, Lars Melgaard Videbæk, Mikael Kjær Poulsen, Christian Tuxen, Sören Möller, Finn Gustafsson et al. · 2021 · JAMA Cardiology
39. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy
    Nikole J. Byrne, Namakkal Soorappan Rajasekaran, E. Dale Abel, Heiko Bugger · 2021 · Free Radical Biology and Medicine
40. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
    Douglas L. Mann, Michael M. Givertz, Justin M. Vader, Randall C. Starling, Palak Mayur Shah, Steven E. McNulty, Kevin Joseph Anstrom, Kenneth B. Margulies, Michael S. Kiernan, Claudius Mahr et al. · 2021 · JAMA Cardiology
41. Kidney and heart failure outcomes associated with SGLT2 inhibitor use
    Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink · 2022 · Nature Reviews Nephrology
42. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
    Aldostefano Porcari, Francesco Cappelli, Christian Nitsche, Daniela Tomasoni, Giulio Sinigiani, Simone Longhi, Luca Bordignon, Ahmad Masri, Matteo Serenelli, Marcus Anthony Urey et al. · 2024 · Journal of the American College of Cardiology
43. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
    Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Naveed A. Sattar, Martina Brueckmann, Waheed Jamal, Daniel Cotton et al. · 2021 · Journal of the American College of Cardiology
44. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( US , UK and Sweden)
    Gianluigi Savarese, Johan Bodegård, Anna Norhammar, Peter Sartipy, Marcus Thuresson, Martín Cowie, Gregg C. Fonarow, Muthiah Vaduganathan, Andrew J.S. Coats · 2021 · European Journal of Heart Failure
45. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction
    Larry A. Allen, Grace E. Venechuk, Colleen Kelley McIlvennan, Robert Lee Page II, Christopher E. Knoepke, Laura J. Helmkamp, Prateeti Khazanie, Pamela N. Peterson, Kenneth Pierce, Geoffrey Harger et al. · 2020 · Circulation
46. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
    Jason R.B. Dyck, Samuel Tobias Sossalla, Nazha Hamdani, Ruben Coronel, Nina Claudia Weber, Peter E. Light, Coert Jozef Zuurbier · 2022 · Journal of Molecular and Cellular Cardiology
47. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
    Ellen M. Apperloo, Brendon Lange Neuen, Robert A Fletcher, Niels Jongs, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, William Guy Herrington, Silvio E. Inzucchi et al. · 2024 · The Lancet Diabetes & Endocrinology
48. National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
    Adhikari, Rishav, Jha, Kunal, Dardari, Zeina, Heyward, James, Blumenthal, Roger S., Eckel, Robert H., Alexander, G. Caleb, Blaha, Michael J. · 2022 · Journal of the American Heart Association
49. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
    João Pedro Ferreira, Faiez M. Zannad, Stuart Pocock, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Martina Brueckmann, Waheed Jamal, Dominik Steubl, Elke Schueler et al. · 2021 · Journal of the American College of Cardiology
50. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
    Guntram Schernthaner, Naim Shehadeh, Ametov As, Anna Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Janež, Péter Kempler, Ilze Konrāde, Nebojsa M. Lalic et al. · 2020 · Cardiovascular Diabetology
51. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction
    Burkert Mathias Pieske, Rolf Wachter, Sanjiv Jayendra Shah, Abigail S. Baldridge, Peter Szeczoedy, Ghionul Ibram, Victor Chengwei Shi, Ziqiang Zhao, Martín Cowie, Aldo Carlos Prado et al. · 2021 · JAMA
52. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics
    Liu, Zhenghong, Ma, Xiaoxuan, Ilyas, Iqra, Zheng, Xueying, Luo, Sihui, Little, Peter J., Kamato, Danielle, Sahebkar, Amirhossein, Wu, Weiming, Weng, Jianping et al. · 2021 · Theranostics
53. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
    Sen, Taha, Heerspink, Hiddo J.L. · 2021 · Cell Metabolism
54. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Alberto Preda, Fabrizio Montecucco, Federico Carbone, Giovanni Guido Camici, Thomas Felix Lüscher, Simon C Kraler, Luca Liberale · 2024 · Cardiovascular Research
55. Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
    Milton Packer, John J.V. McMurray · 2021 · European Journal of Heart Failure
56. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
    Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki A. Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji et al. · 2021 · Cardiovascular Diabetology
57. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
    Rhanderson N. Cardoso, Fabrissio P. Graffunder, Caique M. P. Ternes, Amanda Dantas Ferreira Fernandes, Ana Vitoria Rocha, Gilson Costa Fernandes, Deepak L. Bhatt · 2021 · EClinicalMedicine
58. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Journal of Cardiac Failure
59. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
    Nikolaus Marx, Melanie Jane Davies, Peter J. Grant, Chantal Mathieu, John R. Petrie, Francesco Cosentino, John B. Buse · 2020 · The Lancet Diabetes & Endocrinology
60. Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction
    Yogesh N.V. Reddy, Barry A. Borlaug, Bernard John Gersh · 2022 · Circulation
61. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
    Eva M. Boorsma, Joost C. Beusekamp, Jozine M. ter Maaten, Sylwia Marta Figarska, A.H. Jan Danser, Dirk Jan van Veldhuisen, Peter van der Meer, Hiddo J.L. Heerspink, Kevin Damman, Adriaan A. Voors · 2020 · European Journal of Heart Failure
62. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
    Muhammad Usman, Tariq Jamal Siddiqi, Stefan D. Anker, George L. Bakris, Deepak L. Bhatt, Gerasimos S Filippatos, Gregg C. Fonarow, Stephen John Greene, James L. Januzzi, Muhammad Shahzeb Khan et al. · 2023 · Journal of the American College of Cardiology
63. Association of metabolic syndrome and chronic kidney disease
    Scurt, Florian G., Ganz, Maximilian J., Herzog, Carolin, Bose, Katrin, Mertens, Peter R., Chatzikyrkou, Christos · 2024 · Obesity Reviews
64. Pharmacotherapy of type 2 diabetes: An update and future directions
    Antea J. DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Socrates Mantzoros · 2022 · Metabolism
65. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
    Nick S. Nurmohamed, Jordan M Kraaijenhof, Manuel Mayr, Stephen James Nicholls, Wolfgang Köenig, Alberico Luigi Catapano, Erik S.G. Stroes · 2023 · European Heart Journal
66. Renal Effects of Guideline-Directed Medical Therapies in Heart Failure: A Consensus Document from the Heart Failure Association of the European Society of Cardiology
    Wilfried Müllens, Pieter Martens, Jeffrey Moore Testani, W.H. Wilson Tang, Hadi N. Skouri, Frederik Hendrik Verbrugge, Marat Fudim, Massimo Iacoviello, Jennifer Franke, Andreas J. Flammer et al. · 2022 · European Journal of Heart Failure
67. Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
    Arjun K. Pandey, Iva Okaj, Hargun Kaur, Emilie P. Belley‐Côté, Jia Wang, Alireza Oraii, Alexander Philipp Benz, Linda Johnson, Jack Young, Jorge A. Wong et al. · 2021 · Journal of the American Heart Association
68. Diagnosis and Treatment of Type 2 Diabetes in Adults
    Kalyani, Rita R., Neumiller, Joshua J., Maruthur, Nisa M., Wexler, Deborah J. · 2025 · JAMA
69. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
    Karagiannis, Thomas, Tsapas, Apostolos, Athanasiadou, Eleni, Avgerinos, Ioannis, Liakos, Aris, Matthews, David R., Bekiari, Eleni · 2021 · Diabetes Research and Clinical Practice
70. Coronary blood flow in heart failure: cause, consequence and bystander
    Gerd Heusch · 2022 · Basic Research in Cardiology
71. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
    Nicola Riccardo Pugliese, Pierpaolo Pellicori, Francesco Filidei, Nicolò De Biase, Pasquale Maffia, Tomasz Jan Guzik, Stefano Masi, Stefano Taddei, John G.F. Cleland · 2022 · Cardiovascular Research
72. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging
    Goro Katsuumi, Ippei Shimizu, Masayoshi Suda, Yohko Yoshida, Takaaki Furihata, Yusuke Joki, Chieh-Lun Hsiao, Jiaqi Liang, Shinya Fujiki, Manabu Abe et al. · 2024 · Nature Aging
73. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
    Puglisi, Soraya, Rossini, Alessandro, Poli, Roberta, Dughera, Francesca, Pia, Anna, Terzolo, Massimo, Reimondo, Giuseppe · 2021 · Frontiers in Endocrinology
74. Mitochondrial dysfunction and mitochondrial therapies in heart failure
    Chennan Wu, Zhen Zhang, Weidong Zhang, Xia Liu · 2021 · Pharmacological Research
75. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
    Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Yong‐Qiang Tan, Tiong‐Cheng Yeo, Chi‐Hang Lee, Weiqin Lin, Ching‐Hui Sia · 2021 · Journal of the American Heart Association
76. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
    Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Mark Colquhoun Petrie et al. · 2022 · Circulation
77. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
    Khan, Muhammad Shahzeb, Fonarow, Gregg C., McGuire, Darren K., Hernandez, Adrian F., Vaduganathan, Muthiah, Rosenstock, Julio, Handelsman, Yehuda, Verma, Subodh, Anker, Stefan D., McMurray, John J.V. et al. · 2020 · Circulation
78. Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
    Javed Butler, Muhammad Usman, Muhammad Shahzeb Khan, Stephen John Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos S Filippatos, Andrew J.S. Coats, Stefan D. Anker · 2020 · ESC Heart Failure
79. Novel therapies with precision mechanisms for type 2 diabetes mellitus
    Leigh Perreault, Jay S. Skyler, Julio Rosenstock · 2021 · Nature Reviews Endocrinology
80. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
    Kolkhof, Peter, Hartmann, Elke, Freyberger, Alexius, Pavkovic, Mira, Mathar, Ilka, Sandner, Peter, Droebner, Karoline, Joseph, Amer, Hüser, Jörg, Eitner, Frank · 2021 · American Journal of Nephrology
81. Cardiovascular disease in chronic kidney disease
    Katharina Marx-Schütt, David Z.I. Cherney, Joachim Jankowski, Kunihiro Matsushita, Massimo Nardone, Nikolaus Marx · 2025 · European Heart Journal
82. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation
    Sergio Raposeiras‐Roubín, Ignacio Jesus Amat-Santos, Xavier Rosselló, Rocío González-Ferreiro, Inmaculada González Bermúdez, Diego López‐Otero, Luis Nombela-Franco y, Livia Luciana Gheorghe, Jose L. Diez, Carlos Baladrón et al. · 2025 · New England Journal of Medicine
83. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
    Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Hans‐Peter Brunner‐La Rocca, Stefan P. Janssens, Hiroyuki Tsutsui, Jian Zhang et al. · 2020 · European Heart Journal
84. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Registry
    Agnieszka Kapłon‐Cieślicka, Lina Benson, Ovidiu Dragomir Chioncel, Maria Generosa Crespo-Leiro, Andrew J.S. Coats, Stefan D. Anker, Gerasimos S Filippatos, Frank Thomas Ruschitzka, Camilla Hage, Jarosław Dróżdż et al. · 2021 · European Journal of Heart Failure
85. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial
    Alexander Peikert, Felipe A. Martínez, Muthiah Vaduganathan, Brian Lee Claggett, Ian J. Kulac, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez et al. · 2022 · Circulation Heart Failure
86. Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications
    Haixia Zhang, Ke Yang, Feng Chen, Qianqian Liu, Jingyu Ni, Weilong Cao, Yunqing Hua, Feng He, Zhihao Liu, Lan Li et al. · 2022 · Frontiers in Immunology
87. Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial
    Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra et al. · 2020 · European Journal of Heart Failure
88. Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
    Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting‐Yu Chiou, Tian‐Huei Chu, Lung‐Chih Li, Hwee‐Yeong Ng, Wen‐Chin Lee, Chien‐Te Lee · 2021 · Antioxidants
89. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
    Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, Wojciech Garczorz, Karolina Zimmer, Tomasz Piotr Ilczak, Michał Ćwiertnia, Maciej Błażej Hajduga · 2022 · Cancers
90. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
    William Durante, Ghazaleh Behnammanesh, Kelly J. Peyton · 2021 · International Journal of Molecular Sciences
91. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
    Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Armando Puocci, Antonella De Angelis, Liberata Sportiello et al. · 2022 · Frontiers in Cardiovascular Medicine
92. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
    Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, Stefan D. Anker, Javed Butler, Andrew J.S. Coats, Gerasimos S Filippatos, Stephen John Greene, Theresa A. McDonagh, Piotr P. Ponikowski et al. · 2021 · European Journal of Heart Failure
93. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
    Muhammad Usman, Deepak L. Bhatt, Ishaque Hameed, Stefan D. Anker, ALICE Y.Y. CHENG, Adrian F. Hernandez, W. Schuyler Jones, Muhammad Shahzeb Khan, Mark Colquhoun Petrie, Jacob Allen Udell et al. · 2024 · The Lancet Diabetes & Endocrinology
94. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
    Nikolaos Theodorakis, Maria Nikolaou · 2025 · Biomolecules
95. Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
    Ameya S Kulkarni, Sandra Aleksić, David M. Berger, Felipe Sierra, George A. Kuchel, Nir Barzilai · 2022 · Aging Cell
96. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
    Theresa A. McDonagh, Marco Metra, Marianna Adamo, Roy S. Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Dragomir Chioncel et al. · 2022 · Revista Española de Cardiología
97. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease
    Kristan H. Cleveland, Rick G. Schnellmann · 2022 · Pharmacological Reviews
98. SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
    Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Tobias Sossalla · 2021 · Current Heart Failure Reports
99. Non‐alcoholic fatty liver disease and type 2 diabetes: An update
    Chi‐Ho Lee, David Tak Wai Lui, Karen SL Lam · 2022 · Journal of Diabetes Investigation
100. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
     Milton Packer, Christopher Stuart Wilcox, Jeffrey Moore Testani · 2023 · Circulation